Pharmacokinetics of intravenously administered indomethacin in premature infants

Amin A. Thalji, Ian Carr, Tsu F. Yeh, Devyani Raval, Julie A. Luken, R. S. Pildes

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We studied the pharmacokinetics of indomethacin (0.3 mg/kg) given intravenously in 17 premature infants to promote closure of persistent ductus arteriosus. The decay of indomethacin generally showed an initial rapid distribution (α) phase followed by a slower elimination (β) phase. The mean half-life of elimination (20.7±8 hours) was three times longer, and the mean clearance rate (13±9.5 ml/kg/hour) was seven times less than that reported in adults. The indomethacin clearance rate was linearly correlated with postnatal age (r=0.71, P<0.01). There was strong evidence of later re-entry of indomethacin into the plasma, suggesting that enterohepatic recirculation may be common in premature infants and may contribute to the relatively long half-life of elimination. Our data do not clarify the question of target concentration or minimal exposure time above which permanent closure may occur, but the group of infants who had permanent PDA closure after only one dose (8/17) had a significantly higher plasma indomethacin concentration time integral than the group (9/17) who needed more than one dose (P<0.01). A 24-hour dosage interval was often sufficient when an iv indomethacin bolus of 0.3 mg/kg was used but, below the age of nonresponsiveness to indomethacin, a shorter interval may be preferable as postnatal age increases.

Original languageEnglish
Pages (from-to)995-1000
Number of pages6
JournalThe Journal of Pediatrics
Volume97
Issue number6
DOIs
Publication statusPublished - Jan 1 1980
Externally publishedYes

Fingerprint

Premature Infants
Indomethacin
Pharmacokinetics
Half-Life
Ductus Arteriosus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Pharmacokinetics of intravenously administered indomethacin in premature infants. / Thalji, Amin A.; Carr, Ian; Yeh, Tsu F.; Raval, Devyani; Luken, Julie A.; Pildes, R. S.

In: The Journal of Pediatrics, Vol. 97, No. 6, 01.01.1980, p. 995-1000.

Research output: Contribution to journalArticle

Thalji, Amin A. ; Carr, Ian ; Yeh, Tsu F. ; Raval, Devyani ; Luken, Julie A. ; Pildes, R. S. / Pharmacokinetics of intravenously administered indomethacin in premature infants. In: The Journal of Pediatrics. 1980 ; Vol. 97, No. 6. pp. 995-1000.
@article{2ad8d82d7bfb4a48bfce416e75672b09,
title = "Pharmacokinetics of intravenously administered indomethacin in premature infants",
abstract = "We studied the pharmacokinetics of indomethacin (0.3 mg/kg) given intravenously in 17 premature infants to promote closure of persistent ductus arteriosus. The decay of indomethacin generally showed an initial rapid distribution (α) phase followed by a slower elimination (β) phase. The mean half-life of elimination (20.7±8 hours) was three times longer, and the mean clearance rate (13±9.5 ml/kg/hour) was seven times less than that reported in adults. The indomethacin clearance rate was linearly correlated with postnatal age (r=0.71, P<0.01). There was strong evidence of later re-entry of indomethacin into the plasma, suggesting that enterohepatic recirculation may be common in premature infants and may contribute to the relatively long half-life of elimination. Our data do not clarify the question of target concentration or minimal exposure time above which permanent closure may occur, but the group of infants who had permanent PDA closure after only one dose (8/17) had a significantly higher plasma indomethacin concentration time integral than the group (9/17) who needed more than one dose (P<0.01). A 24-hour dosage interval was often sufficient when an iv indomethacin bolus of 0.3 mg/kg was used but, below the age of nonresponsiveness to indomethacin, a shorter interval may be preferable as postnatal age increases.",
author = "Thalji, {Amin A.} and Ian Carr and Yeh, {Tsu F.} and Devyani Raval and Luken, {Julie A.} and Pildes, {R. S.}",
year = "1980",
month = "1",
day = "1",
doi = "10.1016/S0022-3476(80)80445-8",
language = "English",
volume = "97",
pages = "995--1000",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics of intravenously administered indomethacin in premature infants

AU - Thalji, Amin A.

AU - Carr, Ian

AU - Yeh, Tsu F.

AU - Raval, Devyani

AU - Luken, Julie A.

AU - Pildes, R. S.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - We studied the pharmacokinetics of indomethacin (0.3 mg/kg) given intravenously in 17 premature infants to promote closure of persistent ductus arteriosus. The decay of indomethacin generally showed an initial rapid distribution (α) phase followed by a slower elimination (β) phase. The mean half-life of elimination (20.7±8 hours) was three times longer, and the mean clearance rate (13±9.5 ml/kg/hour) was seven times less than that reported in adults. The indomethacin clearance rate was linearly correlated with postnatal age (r=0.71, P<0.01). There was strong evidence of later re-entry of indomethacin into the plasma, suggesting that enterohepatic recirculation may be common in premature infants and may contribute to the relatively long half-life of elimination. Our data do not clarify the question of target concentration or minimal exposure time above which permanent closure may occur, but the group of infants who had permanent PDA closure after only one dose (8/17) had a significantly higher plasma indomethacin concentration time integral than the group (9/17) who needed more than one dose (P<0.01). A 24-hour dosage interval was often sufficient when an iv indomethacin bolus of 0.3 mg/kg was used but, below the age of nonresponsiveness to indomethacin, a shorter interval may be preferable as postnatal age increases.

AB - We studied the pharmacokinetics of indomethacin (0.3 mg/kg) given intravenously in 17 premature infants to promote closure of persistent ductus arteriosus. The decay of indomethacin generally showed an initial rapid distribution (α) phase followed by a slower elimination (β) phase. The mean half-life of elimination (20.7±8 hours) was three times longer, and the mean clearance rate (13±9.5 ml/kg/hour) was seven times less than that reported in adults. The indomethacin clearance rate was linearly correlated with postnatal age (r=0.71, P<0.01). There was strong evidence of later re-entry of indomethacin into the plasma, suggesting that enterohepatic recirculation may be common in premature infants and may contribute to the relatively long half-life of elimination. Our data do not clarify the question of target concentration or minimal exposure time above which permanent closure may occur, but the group of infants who had permanent PDA closure after only one dose (8/17) had a significantly higher plasma indomethacin concentration time integral than the group (9/17) who needed more than one dose (P<0.01). A 24-hour dosage interval was often sufficient when an iv indomethacin bolus of 0.3 mg/kg was used but, below the age of nonresponsiveness to indomethacin, a shorter interval may be preferable as postnatal age increases.

UR - http://www.scopus.com/inward/record.url?scp=0019127281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019127281&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(80)80445-8

DO - 10.1016/S0022-3476(80)80445-8

M3 - Article

VL - 97

SP - 995

EP - 1000

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -